J Breast Cancer.  2010 Sep;13(3):250-256.

Lymphovascular Invasion and HER2/neu Amplification as Predictive Factors for Axillary Lymph Node Metastasis in Early Breast Cancer Patients

• Gwak G
• Park K
• Shin E
• Han S
• Kim JY
• Kim H
• Kim YD
• Kim HJ
• Kim KW
• Bae BN
• Yang KH
• Park SJ
• Lim SW

Abstract

PURPOSE
Axillary lymph node metastasis (ALNM) can occur even in breast cancer smaller than 2 cm in size. This study was performed to investigate the clinicopathologic factors that affect node metastasis in T1 breast cancer.
METHODS
We reviewed the medical record of 206 T1 breast cancer patients and we divided them into two groups according to the presence or absence of lymph node metastasis. We analyzed the association between ALNM and various clinicopathological predictive factors such as age, tumor size (T1a, T1b, T1c), multiplicity, the histologic grade, the nuclear grade, the presence of lymphovascular invasion (LVI), the estrogen and progesterone receptor status, an HER2/neu expression, the Ki-67 labeling index and the bcl-2 expression.
RESULTS
One hundred and thirty-nine were the node negative group (T1N0) and the remaining 67 cases were allotted to the node positive group (T1N1-3). On the univariate analysis, age (p=0.011), LVI (p<0.001), histologic grade (p=0.019), HER2/neu (p<0.005), Ki-67 (p=0.012) and bcl-2 (p=0.026) were the statistically significant predictive factors related to node metastasis. But on the multivariate analysis, LVI (p<0.001) and HER2/neu (p=0.009) were the statistically significant factors related to node metastasis.
CONCLUSION
LVI and HER2/neu overexpression were related to the increased incidence of ALNM in T1 breast cancer patients. LVI was the most predictive factor of ALNM.

Keyword

Breast neoplasms; HER2/neu; Lymphovascular invasion

MeSH Terms

Breast
Breast Neoplasms
Estrogens
Humans
Incidence
Lymph Nodes
Medical Records
Multivariate Analysis
Neoplasm Metastasis
Receptors, Progesterone
Estrogens
Receptors, Progesterone

Reference

1. Rosen PP, Saigo PE, Braun DW, Weathers E, Kinne DW. Prognosis in stage II (T1N1M0) breast cancer. Ann Surg. 1981. 194:576–584.

2. González-Vela MC, Garijo MF, Fernández FA, Buelta L, Val-Bernal JF. Predictors of axillary lymph node metastases in patients with invasive breast carcinoma by a combination of classical and biological prognostic factors. Pathol Res Pract. 1999. 195:611–618.

3. Tan LG, Tan YY, Heng D, Chan MY. Predictors of axillary lymph node metastases in women with early breast cancer in Singapore. Singapore Med J. 2005. 46:693–697.

4. Port ER, Tan LK, Borgen PI, Van Zee KJ. Incidence of axillary lymph node metastases in T1a and T1b breast carcinoma. Ann Surg Oncol. 1998. 5:23–27.

5. Lee AH, Pinder SE, Macmillan RD, Mitchell M, Ellis IO, Elston CW, et al. Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. Eur J Cancer. 2006. 42:357–362.

6. Shoup M, Malinzak L, Weisenberger J, Aranha GV. Predictors of axillary lymph node metastasis in T1 breast carcinoma. Am Surg. 1999. 65:748–752.

7. Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005. 23:7703–7720.

8. Carcoforo P, Maestroni U, Querzoli P, Lanzara S, Maravegias K, Feggi L, et al. Primary breast cancer features can predict additional lymph node involvement in patients with sentinel node micrometastases. World J Surg. 2006. 30:1653–1657.

9. Mustać E, Matusan-Ilijas K, Marijić B, Smokvina M, Jonjić N. Predicting the likelihood of additional nodal metastases in breast carcinoma patients with positive sentinel node biopsy. Int J Surg Pathol. 2010. 18:36–41.

10. Wasif N, Ye X, Giuliano AE. Survey of ASCO members on management of sentinel node micrometastases in breast cancer: variation in treatment recommendations according to specialty. Ann Surg Oncol. 2009. 16:2442–2449.

11. Park K, Kwak K, Kim J, Lim S, Han S. c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers. Hum Pathol. 2005. 36:634–639.

12. Capdet J, Martel P, Charitansky H, Lim YK, Ferron G, Battle L, et al. Factors predicting the sentinel node metastases in T1 breast cancer tumor: an analysis of 1416 cases. Eur J Surg Oncol. 2009. 35:1245–1249.

13. Kim TH, Bae JW, Kim J, Lee JB, Son GS, Koo BH. Factors related with axillary lymph nodes metastases in T1 invasive ductal carcinomas of the breast. J Breast Cancer. 2006. 9:31–35.

14. Bader AA, Tio J, Petru E, Bühner M, Pfahlberg A, Volkholz H, et al. T1 breast cancer: identification of patients at low risk of axillary lymph node metastases. Breast Cancer Res Treat. 2002. 76:11–17.

15. Tiwari RK, Borgen PI, Wong GY, Cordon-Cardo C, Osborne MP. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res. 1992. 12:419–425.

16. Schneider J, Pollán M, Ruibal A, Jiménez E, Lucas AR, Núñez MI, et al. Histologic grade and CD44 are independent predictors of axillary lymph node invasion in early (T1) breast cancer. Tumour Biol. 1999. 20:319–330.

17. Lauria R, Perrone F, Carlomagno C, De Laurentiis M, Morabito A, Gallo C, et al. The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer. 1995. 76:1772–1778.

18. Gurleyik G, Gurleyik E, Aker F, Aktekin A, Emir S, Gungor O, et al. Lymphovascular invasion, as a prognostic marker in patients with invasive breast cancer. Acta Chir Belg. 2007. 107:284–287.

19. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009. 20:1319–1329.

20. Coombs NJ, Boyages J. Multifocal and multicentric breast cancer: does each focus matter? J Clin Oncol. 2005. 23:7497–7502.

21. Tot T. Clinical relevance of the distribution of the lesions in 500 consecutive breast cancer cases documented in large-format histologic sections. Cancer. 2007. 110:2551–2560.

22. Vlastos G, Rubio IT, Mirza NQ, Newman LA, Aurora R, Alderfer J, et al. Impact of multicentricity on clinical outcome in patients with T1-2, N0-1, M0 breast cancer. Ann Surg Oncol. 2000. 7:581–587.

23. Ferrari A, Dionigi P, Rovera F, Boni L, Limonta G, Garancini S, et al. Multifocality and multicentricity are not contraindications for sentinel lymph node biopsy in breast cancer surgery. World J Surg Oncol. 2006. 4:79.

24. Chen YY, Schnitt SJ. Prognostic factors for patients with breast cancers 1cm and smaller. Breast Cancer Res Treat. 1998. 51:209–225.

25. Davis BW, Gelber RD, Goldhirsch A, Hartmann WH, Locher GW, Reed R, et al. Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer. 1986. 58:2662–2670.

26. de Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007. 96:1504–1513.

27. Bartlett JM, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, et al. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. J Clin Oncol. 2007. 25:4423–4430.

28. Singh Y, Nambu H, Yoshizawa K, Hatano T, Hioki K, Tsubura A. Factors related to axillary lymph node metastasis in T1 breast carcinoma. Oncol Rep. 1998. 5:459–462.

29. Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P, Van Marck E. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer. 1995. 72:354–360.

30. Berardo MD, Elledge RM, de Moor C, Clark GM, Osborne CK, Allred DC. bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer. 1998. 82:1296–1302.

31. Charpin C, Garcia S, Bonnier P, Martini F, Andrac L, Horschowski N, et al. bcl-2 automated and quantitative immunocytochemical assays in breast carcinomas: correlation with 10-year follow-up. J Clin Oncol. 1998. 16:2025–2031.

32. Vargas-Roig LM, Cuello-Carrión FD, Fernández-Escobar N, Daguerre P, Leuzzi M, Ibarra J, et al. Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy. Mol Oncol. 2008. 2:102–111.